GLP1R and diabetes mellitus: Moreover, an analysis of the National Health and Nutrition Examination Survey (NHANES) from 2017 to 2018 found that although one-third of sampled patients with diabetes mellitus were eligible for GLP-1 RAs, in 2018 the use of these agents was limited to only 1 in 100 eligible patients [18].